Filtered By:
Condition: Heart Failure
Countries: USA Health
This page shows you your search results in order of relevance. This is page number 14.
Order by Relevance | Date
Total 212 results found since Jan 2013.
Pharmacoepidemiologic study of association between apparent treatment resistant hypertension, cardiovascular disease and interaction effect by sex and age
CONCLUSION: aTRH was significantly associated with an increased risk of CVD and this association was modified by both sex and age. Further studies are warranted to test these mechanisms.PMID:37274374 | PMC:PMC10237003 | DOI:10.4330/wjc.v15.i5.262
Source: World Journal of Cardiology - June 5, 2023 Category: Cardiology Authors: Julianne Theresa Nelson Longjian Liu Source Type: research
Pregnancy-Associated Takotsubo Cardiomyopathy Hospitalizations in the United States
Am J Physiol Heart Circ Physiol. 2023 Jul 7. doi: 10.1152/ajpheart.00262.2023. Online ahead of print.ABSTRACTTakotsubo cardiomyopathy (TCM) is most common in postmenopausal women aged ≥ 50 years but also affects pregnant individuals. However, there are no national estimates on the prevalence, timing of occurrence, correlates, and outcomes of Pregnancy-associated TCM. Using the Nationwide Inpatient Sample (NIS: 2016-2020), we describe rates of pregnancy-associated TCM hospitalizations among 13 - 49 years old pregnant individuals in the United States by selected demographic, behavioral, hospital, and clinical characteristi...
Source: American Journal of Physiology. Heart and Circulatory Physiology - July 7, 2023 Category: Physiology Authors: Mulubrhan F Mogos Soojung Ahn James M Muchira Sarah Osmundson Mariann R Piano Source Type: research
Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk
Partnership combines Roche ’s proven track record of successfully developing and launching innovative medicines worldwide withAlnylam ’s leadership in RNAi therapeuticsZilebesiran, a Phase 2 RNAi therapeutic, has best-in-disease potential for patients with hypertension at high risk of cardiovascular morbidity and mortality, by robustly and durably lowering blood pressureHypertension, the leading cause of cardiovascular disease, affects more than 1.2 billion adults worldwide. While several therapies exist, a significant unmet need, especially for high risk patients, remains.1Basel, 24 July 2023 - Roche (SIX: RO, ROG; OT...
Source: Roche Media News - July 24, 2023 Category: Pharmaceuticals Source Type: news
Global Economic Burden Associated with Chronic Kidney Disease: A Pragmatic Review of Medical Costs for the Inside CKD Research Programme
ConclusionGlobally, CKD carries a significant economic burden, which increases substantially with increasing disease severity. We identified significant gaps in published costs and inconsistent costing definitions. Cost-effective interventions that target primary prevention and disease progression are essential to reduce CKD burden. Our results can be used to guide cost collection and facilitate better comparisons across countries/regions to inform healthcare policy.
Source: Advances in Therapy - July 26, 2023 Category: Drugs & Pharmacology Source Type: research
Sestrin2 as a Potential Target in Hypertension
Diagnostics (Basel). 2023 Jul 14;13(14):2374. doi: 10.3390/diagnostics13142374.ABSTRACTHypertension is a highly complex, intricate condition affecting millions of individuals across the globe. Nearly half of adults in the United States are diagnosed with hypertension, with incident rates projected to rise over the next decade. Hypertension is a precursor to many cardiovascular diseases including atherosclerosis, stroke, myocardial infarction, heart failure, and peripheral artery disease. This review describes the major processes contributing to the development of hypertension and how Sestrin2 (Sesn2), an antioxidative prot...
Source: Atherosclerosis - July 29, 2023 Category: Cardiology Authors: Steven Didik Hao Wang Adewale Segun James Lily Slotabec Ji Li Source Type: research
To support the use of NT-proBNP to better detect heart failure in patients with type 2 diabetes
ConclusionThese determinants might contribute to investigate the NT-proBNP in T2DM sufferers. A decision support system to appropriately ease the prescription of NT-proBNP might be therefore implemented in primary care settings.
Source: Endocrine - August 28, 2023 Category: Endocrinology Source Type: research
